Company news: Shire, Sanofi

Share this article:
Shire announced Wednesday that it is looking to expand the indication for its ADHD medication Vyvanse. The company is seeking approval for use of the stimulant as a maintenance drug for children between the ages of 6 and 17. It is currently cleared for maintenance therapy among adults. Approval would make it the only stimulant approved for maintenance among this age group. FDA's action date is April 29, 2013.

Sanofi is expected to clarify layoff plans at meetings September 25 and October 3, reported Reuters, which attributed the information to union sources. Reuters' sources said they expect Sanofi to cut about 2,500 research and support jobs in France. Sanofi told Reuters meeting dates had not been set, but that it will present its employment plans to the works council this month.
Share this article:

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.